Oxford Glyco jumps 12% on hopes for a rival bid
Oxford Glycosciences, the biotech company seeking an all-share deal with Cambridge Antibody Technology, could become the subject of a bid battle after it revealed yesterday that "a number of parties, including Celltech" had requested information on its business.
It is understood there have been three or four expressions of interest. Celltech, the UK's biggest biotech company, is considering making a cash offer. Analysts think the US antibody specialist Mederex, with whom OGS already collaborates, could also be interested.
Shares in Oxford Glycosciences rose 12 per cent to 192.5p on the possibility of an auction. CAT's offer now values OGS, whose chief executive is David Ebsworth, at £94m, or 168p a share. This is some way below its target's current market value of £107m as the market bets on a higher offer being made.
Any rival bidder must make its move before 11 March when shareholders are due to vote on the CAT-OGS merger.
Analysts were divided on the likelihood of Celltech entering the fray. Sam Fazeli, an industry analyst at Nomura, said: "The same technology synergy that is proposed for the CAT-OGS merger also exists for Celltech and OGS."
But Emma Palmer, at WestLB Panmure, said a deal could distract Celltech from its existing business, particularly as it is also searching for a new chief executive. "We feel the company may be better served by making product acquisitions," she said.
Celltech declined to comment on its interest in OGS, or on reports its new chief executive will be Goran Ando, the research and development director at Pharmacia.
Dan Mahony, at Morgan Stanley, expressed doubts about the rationale of a Celltech bid. "CAT-OGS makes a lot of sense as it brings expertise in certain areas and more clinical development experts. Celltech already has these things."
Peter Chambre, CAT's chief executive, emphasised that his offer was the only formal one on the table. He said: "OGS brings us a stronger pipeline, is a good research and development fit and gives us more financial power." It would create a company that "could compete with the top tier of biotech companies and give UK investors a second, strong publicly quoted biotech company to choose from," he said.
Celltech shares rose 7p to 338.25p.
Matt Smith is set to join cast of Jane Austen classic - with a twist
Olympic diver has made his modelling debut for Adidas
- 2 Scottish independence: Learn from Quebec's mistakes and beware of promises. Vote Yes.
- 3 'Necrophilia-obsessed' girl among double murder accused in three-way sex case
- 4 A bottle of wine a day is not bad for you and abstaining is worse than drinking, scientist claims
Thailand beach murders: Thai PM suggests 'attractive' female tourists cannot expect to be safe wearing bikinis
Scottish independence: Final opinion polls show undecided voters could swing result either way
Isis release 'Flames of War' video warning Obama of attacks troops could face in Iraq
Jennifer Lawrence 'naked sex video' will be leaked next, threatens 4Chan celebrity photo hacker
Hitler’s former food taster reveals the horrors of the Wolf’s Lair
Daniele Watts: Django Unchained actress detained by Los Angeles police after being mistaken for a prostitute
Scottish independence referendum: A nation divided against itself
The political class is doing what Hitler couldn’t – destroying Britain
Scottish independence: Nationalist leader Jim Sillars threatens pro-union companies with 'day of reckoning' after independence
Portuguese academic says British are 'filthy, violent and drunk'
Scottish independence: David Cameron is becoming the 'George Bush of Britain'
iJobs Money & Business
£18000 - £23000 per annum + Comission: SThree: The SThree group is a world lea...
£18000 - £23000 per annum + Commission: SThree: Real Staffing are currently lo...
£20000 - £25000 per annum + OTE £35,000 first year: SThree: The SThree group i...
£20 - 24k (Uncapped Commission - £35k Year 1 OTE): Guru Careers: We are seekin...